中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

41 records (took 0.028 seconds)

    PEPTIDES AND THEIR UTILITY IN MODULATION OF BEHAVIOR OF CELLS EXPRESSING alpha3beta1 INTEGRINS
    2.
    发明申请
    PEPTIDES AND THEIR UTILITY IN MODULATION OF BEHAVIOR OF CELLS EXPRESSING alpha3beta1 INTEGRINS 有权
    肽及其在表达α3β1整合的细胞行为调节中的应用

    公开(公告)号：US20080249026A1

    公开(公告)日：2008-10-09

    申请号：US11466718

    申请日：2006-08-23

    Applicant: David D. Roberts ,  Henry C. Krutzsch

    Inventor： David D. Roberts ,  Henry C. Krutzsch

    IPC: A61K38/10 ,  C07K5/00 ,  C07K7/06 ,  C07K7/08 ,  A61P35/00 ,  C12N5/00 ,  A61P9/00 ,  A61K38/07 ,  A61K38/08

    CPC classification number: C07K7/06 ,  A61K38/00

    Abstract: The present invention relates to a peptide comprising the sequence R1-X1-X2-X3-X4-R2, wherein X1 is selected from the group consisting of N, Q, D and S; X2 is selected from the group consisting of V, I and L; X1 is selected from the group consisting of R and K; and X4 is selected from the group consisting of V, I, L and F; R1 is a hydrogen or a peptide of 1 to 6 amino acids, and acyl or an aryl group; and R2 is a peptide of 1 to 3 amino acids, a hydroxide or an amide. The invention also relates to partial or full retro-inverso peptides comprising the above sequences. The invention also relates to peptide-substrate combination comprising a substrate suitable for cell growth and the peptide of the invention, and to a vascular graft and an artificial blood vessel comprising the peptide-substrate combination. The invention also relates to a pharmaceutical composition and a peptide conjugate comprising the peptide of the invention. The invention also relates to a method of inhibiting adhesion of a cell expressing α3β1 integrin to an extracellular matrix, inhibiting α3β1-integrin-mediated cell motility, inhibiting α3β1-integrin mediated cell proliferation, promoting α3β1-integrin mediated cell proliferation and inhibiting angiogenesis utilizing the peptides of the invention.

    Abstract translation: 本发明涉及包含序列R 1 -X 1 -X 2 -X 3 -X 3的肽， X 4 -R 2，其中X 1选自N，Q，D和S; X 2选自V，I和L; X 1选自R和K; 并且X 4选自V，I，L和F; R 1是氢或1至6个氨基酸的肽，酰基或芳基; R 2是1至3个氨基酸的肽，氢氧化物或酰胺。 本发明还涉及包含上述序列的部分或全部逆转肽。 本发明还涉及包含适合于细胞生长的底物和本发明的肽的肽 - 底物组合以及包含肽 - 底物组合的血管移植物和人造血管。 本发明还涉及包含本发明的肽的药物组合物和肽缀合物。 本发明还涉及一种抑制细胞外基质表达α3β1整联蛋白的细胞粘附的方法，抑制α3β1， 整合素介导的细胞运动，抑制α3-β1整联蛋白介导的细胞增殖，促进α3β - 整合素介导的细胞增殖并利用本发明的肽抑制血管生成。

    Prevention of tissue ischemia, related methods and compositions
    8.
    发明授权
    Prevention of tissue ischemia, related methods and compositions 有权
    预防组织缺血，相关方法和组合物

    公开(公告)号：US08236313B2

    公开(公告)日：2012-08-07

    申请号：US12444364

    申请日：2007-10-05

    Applicant: Jeffrey S. Isenberg ,  David D. Roberts ,  William A. Frazier

    Inventor： Jeffrey S. Isenberg ,  David D. Roberts ,  William A. Frazier

    IPC: A61K39/395

    CPC classification number: C07K16/18 ,  A61K39/3955 ,  A61K45/06 ,  A61K48/00 ,  A61K2039/505 ,  B01J21/063 ,  B01J21/12 ,  B01J23/002 ,  B01J23/30 ,  B01J27/188 ,  B01J37/0205 ,  B01J2523/00 ,  C07C45/002 ,  C07C45/52 ,  C07C51/235 ,  C07C51/252 ,  C07C253/26 ,  C07K14/78 ,  C07K2317/76 ,  G01N33/6887 ,  G01N33/6893 ,  G01N2333/705 ,  C07C47/22 ,  C07C57/04 ,  B01J2523/15 ,  B01J2523/51 ,  B01J2523/69 ,  B01J2523/41

    Abstract: Provided herein are compositions and methods for preventing, ameliorating, and/or reducing tissue ischemia and/or tissue damage due to ischemia, increasing blood vessel diameter, blood flow and tissue perfusion in the presence of vascular disease including peripheral vascular disease, atherosclerotic vascular disease, coronary artery disease, stroke and influencing other conditions, by suppressing CD47 and/or blocking TSP1 and/or CD47 activity or interaction. Influencing the interaction of CD47-TSP1 in blood vessels allows for control of blood vessel diameter and blood flow, and permits modification of blood pressure and cardiac function. Under conditions of decreased blood flow, for instance through injury or atherosclerosis, blocking TSP1-CD47 interaction allows blood vessels to dilate and increases blood flow, tissue perfusion and tissue survival. This in turn reduces or prevents tissue necrosis and death. The therapeutics identified herein allow for precise regulation of blood flow to tissues and organs which need it, while substantially avoiding systemic complications. Methods and compositions described herein can be used to increase tissue survival under conditions of trauma and surgery, as well as conditions of chronic vascular disease. Also disclosed are methods for the treatment of elderly subjects using agents that affect TSP1 and CD47 and thereby affect tissue perfusion. Additionally, provided herein are compositions and methods for influencing blood coagulation, allowing for controlled increased or decreased blood clotting. Additionally, provided herein are compositions and methods for decreasing blood flow, as in the case of cancer through mimicking the effects of TSP1 and CD47 on blood vessel diameter and blood flow.

    Abstract translation: 本文提供的是用于预防，改善和/或减少由于缺血引起的组织缺血和/或组织损伤，增加血管直径，血流量和组织灌注的组合物和方法，所述血管疾病包括外周血管疾病，动脉粥样硬化性血管疾病 ，冠状动脉疾病，中风和影响其他病症，通过抑制CD47和/或阻断TSP1和/或CD47活性或相互作用。 影响CD47-TSP1在血管中的相互作用允许控制血管直径和血流量，并允许改变血压和心脏功能。 在血液流量减少的情况下，例如通过损伤或动脉粥样硬化，阻断TSP1-CD47相互作用使血管扩张并增加血流量，组织灌注和组织存活。 这又减少或预防组织坏死和死亡。 本文鉴定的治疗剂允许精确调节需要它的组织和器官的血流，同时基本上避免系统并发症。 本文描述的方法和组合物可用于在创伤和手术的条件下以及慢性血管疾病的病症中增加组织存活。 还公开了使用影响TSP1和CD47并因此影响组织灌注的试剂治疗老年受试者的方法。 此外，本文提供了影响血液凝固的组合物和方法，允许控制增加或减少血液凝固。 此外，本文提供的是通过模拟TSP1和CD47对血管直径和血流量的影响来减少血流量的组合物和方法，如在癌症的情况下。

    Method and tool for handling micro-mechanical structures
    9.
    发明授权
    Method and tool for handling micro-mechanical structures 失效
    用于处理微机械结构的方法和工具

    公开(公告)号：US5966591A

    公开(公告)日：1999-10-12

    申请号：US908648

    申请日：1997-08-07

    Applicant: David D. Roberts

    Inventor： David D. Roberts

    IPC: H01L21/00 ,  H01L21/673 ,  H01L21/44

    CPC classification number: H01L21/67138 ,  B81C99/002

    Abstract: A method of forming and handling an array of micro-devices such as thin film devices that enables simultaneous mass handling and processing of these thin film devices. A plurality of micro-devices and links are simultaneously formed on a wafer, with the links interconnecting the micro-devices for maintaining a unitary array structure. A matrix of magnetic strips is then formed to impart added overall tensile strength to the array. The magnetic strips are secured to the links and form a planar support grid therewith. The array of micro-devices is then released from the wafer and lifted therefrom by means of a magnetic pick-up tool. Using the pick-up tool, the array is transferred onto a magnetic chuck which securely retains the array. Conductive wires are bonded to a row of micro-devices devices which are then separated from the array into individual micro-devices.

    Abstract translation: 一种形成和处理诸如薄膜器件的微器件阵列的方法，其能够同时进行质量处理和处理这些薄膜器件。 多个微器件和链节同时形成在晶片上，其中链节互连微器件以维持整体阵列结构。 然后形成磁条矩阵以赋予阵列增加的总拉伸强度。 磁条被固定到链节上并与其形成平面支撑格栅。 然后将微器件阵列从晶片释放并通过磁力拾取工具从其上提升。 使用拾取工具，将阵列转移到牢固地保持阵列的磁性卡盘上。 导电线结合到一排微器件器件，然后将其从阵列分离成单独的微器件。

    Carbohydrate receptor for bacteria and method for use thereof
    10.
    发明授权
    Carbohydrate receptor for bacteria and method for use thereof 失效
    细菌的碳水化合物受体及其使用方法

    公开(公告)号：US5386027A

    公开(公告)日：1995-01-31

    申请号：US60134

    申请日：1993-05-13

    Applicant: Howard C. Krivan ,  Victor Ginsburg ,  David D. Roberts

    Inventor： Howard C. Krivan ,  Victor Ginsburg ,  David D. Roberts

    IPC: A61K31/70 ,  G01N33/569 ,  C08B37/00 ,  A61K39/02

    CPC classification number: G01N33/56911 ,  A61K31/70 ,  Y10S435/803 ,  Y10S435/851 ,  Y10S435/874 ,  Y10S435/882 ,  Y10S435/885

    Abstract: A carbohydrate receptor for pathogenic bacteria is a purified carbohydrate compound that is a member selected from the group consisting of fucosyl-asialo GM1, asialo GM1, and asialo GM2. The receptor can be included in a composition having a pharmaceutically acceptable carrier. The receptor may be used for purifying, detecting, or removing bacteria from diseased tissue. The structure of the receptor is N-acetylagalctosamine-beta-1-4-galactose-beta-1-4-glucose, abbreviated GalNAc.beta.1-4Gal.beta.1-4Glc. The receptor is present in human and animal tissues as complex molecule and can serve as the attachment site for bacterial infection. For example, fucosyl-asialo GM1, asialo GM1, and asialo GM2 are three biological molecules which occur in cell membranes and contain the carbohydrate receptor.

    Abstract translation: 用于致病细菌的碳水化合物受体是选自岩藻糖基 - 脱ial GM1，脱ial GM1和唾液酸GM2的成员的纯化碳水化合物化合物。 受体可以包含在具有药学上可接受的载体的组合物中。 该受体可用于纯化，检测或从患病组织中除去细菌。 受体的结构是N-乙酰加己酰胺-β-1-4-半乳糖-β-1-4-葡萄糖，缩写为GalNAcβ1-4Galβ1-4Glc。 受体作为复合分子存在于人和动物组织中，可作为细菌感染的附着位点。 例如，岩藻糖基唾液酸GM1，脱ial GM1和脱ial GM2是发生在细胞膜中并含有碳水化合物受体的三种生物分子。

Patent Agency Ranking